ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.



https://recodetx.com/

Recode Therapeutics announced it raised $260 Million in an amended filing from an offering of $290 Million

Company Information

Related People

Funding Insights

Recode Therapeutics announced it raised $260 Million in an amended filing from an offering of $290 Million

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information